COVID-19 и сердечно-сосудистые заболевания
https://doi.org/10.15372/ATER20200207
Аннотация
На начало июня 2020 г. в мире выявлено более 7 млн человек с COVID-19 – новой коронавирусной инфекцией, распространившейся по всему миру, более 400 тысяч человек умерло. В России количество заболевших превысило 470 000 человек, погибло более 5900 [https:// covid19-2020.info/]. Все больше исследователей сообщают о высокой вероятности развития инфекции и неблагоприятном течении болезни у лиц с сердечно-сосудистыми заболеваниями, что обусловливает необходимость изучения влияния SARS-CoV-2 на сердечно-сосудистую систему. Дан анализ публикаций за 2020 г. из баз данных PubMed, Google Scholar и E-library, посвященных этому вопросу.
Об авторах
Я. В. Полонская
НИИ терапии и профилактической медицины – филиал ФГБНУ ФИЦ Институт цитологии и генетики СО РАН
Россия
Россия
Полонская Яна Владимировна – доктор биологических наук, старший научный сотрудник, лаборатория клинических биохимических и гормональных исследований терапевтических заболеваний
630089, Новосибирск, ул. Бориса Богаткова, 175/1
Е. В. Каштанова
НИИ терапии и профилактической медицины – филиал ФГБНУ ФИЦ Институт цитологии и генетики СО РАН
Россия
Россия
Каштанова Елена Владимировна – доктор биологических наук, заведующий лабораторией клинических биохимических и гормональных исследований терапевтических заболеваний
630089, Новосибирск, ул. Бориса Богаткова, 175/1
Е. М. Стахнёва
НИИ терапии и профилактической медицины – филиал ФГБНУ ФИЦ Институт цитологии и генетики СО РАН
Россия
Россия
Стахнёва Екатерина Михайловна – кандидат биологических наук, старший научный сотрудник, лаборатория клинических биохимических и гормональных исследований терапевтических заболеваний
630089, Новосибирск, ул. Бориса Богаткова, 175/1
Е. В. Садовский
НИИ терапии и профилактической медицины – филиал ФГБНУ ФИЦ Институт цитологии и генетики СО РАН
Россия
Россия
Садовский Евгений Викторович – младший научный сотрудник, лаборатория клинических биохимических и гормональных исследований терапевтических заболеваний
630089, Новосибирск, ул. Бориса Богаткова, 175/1
Ю. И. Рагино
НИИ терапии и профилактической медицины – филиал ФГБНУ ФИЦ Институт цитологии и генетики СО РАН
Россия
Россия
Рагино Юлия Игоревна – доктор медицинских наук, чл.-корр. РАН, руководитель НИИТПМ – филиал ИЦиГ СО РАН
630089, Новосибирск, ул. Бориса Богаткова, 175/1
Список литературы
1. Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395: 497–506.
2. Carlos W.G., Dela Cruz C.S., Cao B., et al. Novel Wuhan (2019-nCoV) Coronavirus. Am. J. Respir. Crit. Care. Med. 2020; 201: P7-P8.
3. WHO. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019 – nCoV) [online]. (2020). Available: https:// www.who.int/news-room/detail/30-01-2020-statementon-the-second-meeting-of-theinternational-health-regulations-(2005)-emergency-committee-regarding-theoutbreak-of-novelcoronavirus-(2019-ncov)а
4. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/ naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it 2 5. https://covid19-2020.info/
5. Gaythorpe K., Imai N., Cuomo-Dannenburg G., et al. With support from other volunteers from the MRC Centre. et al. Symptom progression of COVID-19. Imperial College London (11-03-2020). doi: https://doi.org/10.25561/77344
6. Lai C.C., Liu Y.H., Wang C.Y., et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J. Microbiol. Immunol. Infect. 2020. doi: 10.1016/j.jmii.2020.02.012
7. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020; 41: 145–151. doi: 10.3760/cma.j.issn.0254-6450.2020.02.003
8. Arentz M.Y., Klaff L., Lokhandwala S., et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA. 2020; doi: 10.1001/jama.2020.4326
9. Yang X., Yu Y., Xu J., Shu H., et al. Clinical course and outcomes of critically ill patients with SARSCoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 2020; doi: 10.1016/S2213-2600(20)30079-5
10. Liu K., Fang Y.Y., Deng Y., et al.. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin. Med. J. (Engl). 2020; 133: 1025–1031.
11. Wang D., Hu B., Hu C., et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020, doi: 10.1001/jama.2020.1585.
12. Zhang J.J., Dong X., Cao Y.Y., et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020. doi: 10.1111/all.14238.
13. Mo P., Xing Y., Xiao Y., et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin. Infect. Dis. 2020. doi: 10.1093/cid/ciaa270
14. Guo T., Fan Y., Chen M., et al.Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020. doi: 10.1001/jamacardio.2020.1017
15. Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020. doi: 10.1016/S0140-6736(20)30566-3
16. Chen T., Wu D., Chen H., et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020; 368:m1091.
17. Wang L., He W., Yu X., et al. Coronavirus Disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J. Infection. 2020. https://doi.org/10.1016/j.jinf.2020.03.019
18. Shi S., Qin M., Shen B., et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020, doi: 10.1001/jamacardio.2020.0950
19. Lian J., Jin X., Hao S., et al. Analysis of epidemiological and clinical features in older patients with corona virus disease 2019 (COVID-19) out of Wuhan. Clin. Infect. Dis. 2020; pii: ciaa242. https://doi.org/10.1093/cid/ciaa242
20. Guan W.J.N.Z., Hu Y., Liang W.H., et al. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020, doi: 10.1056/NEJMoa2002032
21. Guan W., Ph D., Liang W., et al. Comorbidity and its impact on 1,590 patients with COVID-19 in China: A Nationwide Analysis. Eur. Respir. J. 2020. https://doi.org/10.1183/13993003.00547-2020
22. Mancia G., Rea F., Ludergnani M., Apolone G., Corrao G. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. N. Engl. J. Med. 2020, doi: 10.1056/NEJMoa2006923
23. Mehra M.R., Desai S.S., Kuy S., Henry T.D. and Patel A.N. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N. Engl. J. Med. 2020, doi: 10.1056/NEJMoa2007621
24. Reynolds H.R., Adhikari S., Pulgarin C., et al. ReninAngiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N. Engl. J. Med. 2020. doi: 10.1056/ NEJMoa2008975
25. Du R.-H., Liang L.-R., Yang C.-Q. et al. Predictors of Mortality for Patients with COVID-19 Pneumonia Caused by SARS-CoV-2: A Prospective Cohort Study. Eur. Res. 2020; 55 (4). doi: 10.1183/13993003.00524-2020 11
26. Characteristics of COVID-19 patients dying in Italy Report based on available data on March 20th, 2020 https://www.epicentro.iss.it/coronavirus/bollettino/Report-COVID-2019_20_marzo_eng.pdf
27. Yingzhen Du, Lei Tu, Pingjun Zhu, et al. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study AJRCCM Articles in Press. Published April 03, 2020 as 10.1164/rccm.202003-0543OC Copyright © 2020 by the American. www.atsjournals.org/doi/pdf/10.1164/rccm.202003-0543OC
28. Chen T. Wu D., Chen H., et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. Br Med J. 2020;1091(March): m1091.https://doi.org/oi.org/doi:10.1136/bmj.m1091 Li B
29. Yang J., Zhao F.L. et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin. Res. Cardiol. 2020; (0123456789). https://doi.org/10.1007/s00392-020-01626-9
30. Yang J., Zheng Y., Gou X., et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and metaanalysis. Int. J. Infect. Dis. 2020 Mar 12. pii: S1201- 9712(20)30136-3. doi: 10.1016/j.ijid.2020.03.017
31. Inciardi R.M.A.M., Lupi L., Cani D.S., et al. Characteristics and outcomes of patients hospitalized for COVID19 and cardiac disease in Northern Italy. Eur. Heart J. 2020, doi: 10.1093/eurheartj/ehaa388
32. Wei J.F., Huang F.Y., Xiong T.Y. et al. Acute myocardial injury is common in patients with covid-19 and impairs their prognosis. Heart. 2020. doi: 10.1136/heartjnl-2020-317007
33. Chen C., Zhou Y., Wang D.W. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz. 2020; 5: 1–3. doi: 10.1007/s00059-020-04909-z. 4
34. Arentz M., Yim E., Klaff L. et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state. JAMA. 2020; 323 (16): 1612– 1614. doi: 10.1001/jama.2020.4326. 6
35. Hui H., Zhang Y., Yang X. et al. Clinical and radiographic features of cardiac injury in patients with 2019 novel coronavirus pneumonia. 2020: 2020.02.24.20027052. 8
36. Xu Z., Shi L., Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020; 8: 420–422.
37. Varga Z., Flammer A.J., Steiger P. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020; 395: 1417–1418.
38. Hendren N.S., Drazner M.H., Bozkurt B., Cooper L.T., Jr. Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome. Circulation. 2020, doi: 10.1161/CIRCULATIONAHA.120.047349
39. Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S., et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020, doi: 10.1001/jamainternmed.2020.0994
40. Liu J., Li S., Liu J., et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. medRxiv. 2020 2020.02.16.20023671
41. Guan W. J., Ni Z.Y., Hu Y., et al. Clinical characteristics of 2019 novel coronavirus infection in China. MedRxiv. doi: 10.1101/2020.02.06.20020974
42. Lippi G., Lavie C.J., Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease (COVID-19): Evidence from a meta-analysis. Prog. Cardiovasc. Dis. 2020. [Epub ahead of print]. doi: 101016/j.pcad.2020.03.001
43. Yingzhen Du, Lei Tu, Pingjun Zhu, et al. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study AJRCCM Articles in Press. Published April 03, 2020 as 10.1164/rccm.202003-0543OC.
44. Zhou F., Yu T., Du R. et al. Clinical course and risk factorsfor mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020.
45. Zheng Y.Y., Ma Y., Zhang J., et al. COVID-19 and the cardiovascular system. Nat. Rev. Cardiol. 2020, doi: 101038/s41569-020-0360-5
46. Hoffmann M., Kleine-Weber H., Schroeder S. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. March 5, 2020; doi: 101016/j.cell.2020.02.052. [epub ahead of print]
47. Tikellis C., Thomas M.C. Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease. Int. J. Pept. 2012; 2012: 256294-256294. doi: 101155/2012/256294
48. Zhang H., Penninger J.M., Li Y., et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. March 3, 2020; doi: 101007/s00134-020-05985-9
49. Ferrario C.M., Jessup J., Chappell M.C., Averill D.B., Brosnihan K.B., Tallant E.A., Diz D.I. Gallagher P.E. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005; 111: 2605–2610.
50. Zisman L.S., Keller R.S., Weaver B., Lin Q., Speth R., Bristow M.R. Canver C.C. Increased angiotensin- (1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensinconverting enzyme Homologue ACE2. Circulation. 2003; 108: 1707–1712.
51. Ishiyama Y., Gallagher P.E., Averill D.B., Tallant E.A., Brosnihan K.B. Ferrario C.M. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004; 43: 970–976.
52. Epelman S., Tang W.H., Chen S.Y., Van Lente F., Francis G.S., Sen S. Detection of soluble angiotensinconverting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the reninangiotensin-aldosterone system. J. Am. Coll. Cardiol. 2008; 52: 750–754.
53. Ohtsuki M., Morimoto S.I., Izawa H., Ismail T.F., Ishibashi-Ueda H., Kato Y., Horii T., Isomura T., Suma H., Nomura M., Hishida H., Kurahashi H. and Ozaki Y. Angiotensin converting enzyme 2 gene expression increased compensatory for left ventricular remodeling in patients with end-stage heart failure. Int. J. Cardiol. 2010; 145: 333–334.
54. Sama I.E.R.A., Santema B.T., van Goor H., ter Maaten J.M., Cleland J.G.F., Rienstra M., Friedrich A.W., Samani N.J., Ng L.L., Dickstein K., Lang C.C., Filippatos G., Anker S.D., Ponikowski P., Metra M., van Veldhuisen D.J., Voors A.A. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. Eur. Heart J. 2020, doi: 10.1093/eurheartj/ehaa373
55. Guo J., Huang Z., Lin L. Lv J. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J. Am. Heart Assoc. 2020; 9: e016219.
56. Imai Y., Kuba K., Rao S., Huan Y., Guo F., Guan B., Yang P., Sarao R., Wada T., Leong-Poi H., Crackower M.A., Fukamizu A., Hui C.C., Hein L., Uhlig S., Slutsky A.S., Jiang C. Penninger J.M. Angiotensinconverting enzyme 2 protects from severe acute lung failure. Nature. 2005; 436: 112–116.
57. Raiden S., Nahmod K., Nahmod V., Semeniuk G., Pereira Y., Alvarez C., Giordano M. Geffner J.R. Nonpeptide antagonists of AT1 receptor for angiotensin II delay the onset of acute respiratory distress syndrome. J. Pharmacol. Exp. Ther. 2002; 303: 45–51.
58. Hui D.S.C., Zumla A. Severe acute respiratory syndrome: historical, epidemiologic, and clinical features. Infect. Dis. Clin. North Am. 2019; 33 (4): 869–889. doi: 10.1016/j.idc.2019.07.001
59. Azhar E.I., Hui D.S.C., Memish Z.A., et al. The Middle East respiratory syndrome (MERS). Infect Dis. Clin. North Am. 2019; 33 (4): 891–905. doi: 101016/j.idc.2019.08.001
60. Li G., Fan Y., Lai Y., et al. Coronavirus infections and immune responses. Med. Virol. 2020; 92 (4): 424– 32. doi: 101002/jmv.25685
61. Channappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol. 2017; 39 (5): 529–539. doi:101007/s00281-017-0629-x
62. Tang N., Li D., Wang X., et al. Abnormal Coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 2020. doi: 101H11/jth14768
63. Klok F.A., Kuip M., van der Meer N.J.M., et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020. doi: 10.1016/j.thromres.2020.04.013
64. Varga Z., Flammer A.J., Steiger P., et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020; 395: 1417–1418.
Рецензия
Для цитирования:
Полонская Я.В., Каштанова Е.В., Стахнёва Е.М., Садовский Е.В., Рагино Ю.И. COVID-19 и сердечно-сосудистые заболевания. Атеросклероз. 2020;16(2):73-79. https://doi.org/10.15372/ATER20200207
For citation:
Polonskaya Ya.V., Kashtanova E.V., Stakhneva E.M., Sadowski E.V., Ragino Yu.I. COVID-19 and cardiovascular diseases. Ateroscleroz. 2020;16(2):73-79. (In Russ.) https://doi.org/10.15372/ATER20200207
Просмотров:
1437
Послать статью по эл. почте 